NYSEAMERICAN:ISRIsoRay Stock Price, Forecast & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IsoRay in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IsoRay.

IsoRay is scheduled to release its next quarterly earnings announcement on Tuesday, September 22nd 2020. View our earnings forecast for IsoRay.

IsoRay, Inc. (NYSEAMERICAN:ISR) announced its quarterly earnings data on Tuesday, May, 12th. The healthcare company reported ($0.01) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.01). The healthcare company earned $2.88 million during the quarter, compared to analysts' expectations of $2.76 million. View IsoRay's earnings history.

2 analysts have issued 12 month target prices for IsoRay's shares. Their forecasts range from $1.25 to $1.75. On average, they anticipate IsoRay's share price to reach $1.50 in the next year. This suggests a possible upside of 127.3% from the stock's current price. View analysts' price targets for IsoRay.

Media headlines about ISR stock have been trending neutral recently, according to InfoTrie. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. IsoRay earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news headlines about the healthcare company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about IsoRay.

IsoRay saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 1,730,000 shares, a drop of 20.3% from the June 15th total of 2,170,000 shares. Based on an average daily volume of 478,900 shares, the short-interest ratio is currently 3.6 days. Currently, 2.6% of the company's stock are short sold. View IsoRay's Current Options Chain.

Some companies that are related to IsoRay include Retractable Technologies (RVP), CRH Medical (CRHM), CRH Medical (CRHM), SDI (SDI), Milestone Scientific (MLSS), Omega Diagnostics Group (ODX), Daxor (DXR), Daxor (DXR), TSO3 (TOS), Impression Healthcare (IHL), G Medical (GMV), TransEnterix (TRXC), Akers Biosciences (AKR), Relevium Technologies (RLV) and Vigil Health Solutions (VGL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other IsoRay investors own include Brainstorm Cell Therapeutics (BCLI), Opko Health (OPK), Bausch Health Companies (BHC), NovaBay Pharmaceuticals (NBY), MannKind (MNKD), TherapeuticsMD (TXMD), Anavex Life Sciences (AVXL), Plug Power (PLUG), Catalyst Pharmaceuticals (CPRX) and Inovio Pharmaceuticals (INO).

IsoRay trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."

Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ISR stock can currently be purchased for approximately $0.66.

IsoRay has a market capitalization of $44.65 million. IsoRay employs 38 workers across the globe.

The official website for IsoRay is isoray.com.

IsoRay's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company can be reached via phone at +1-509-3751202.